Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: Attention deficit hyperactivity disorder (ADHD) is the most diagnosed behavioural disorder in children and adolescents; prevalence has been estimated around 5%. Studies have shown an increase in the use of ADHD medications during the last years. The aim of the present study was to learn the pattern and the evolution of ADHD medication consumption in Castilla y León (Spain). Method: Consumption data for the period 1992–2009 were obtained from databases containing information upon consumption and cost of medications dispensed by pharmacies at the expense of the Spanish National Health System. The data were expressed in defined daily doses (DDDs) per 1000 inhabitants per day (DDD/1000 inhabitants/day). A model to forecast consumption was built. Results: Attention deficit hyperactivity disorder medication consumption increased in Castilla y León from 0.1 DDD/1000 inhabitants/day in 1992 to 1.5 DDD/1000 inhabitants/day in 2009; expected consumption will reach 2.5 DDD/1000 inhabitants/day by 2013. The drugs accounting for this increase were mainly made up of methylphenidate preparations (1.4 DDD/1000 inhabitants/day in 2009). From 1992 to 1999, there was a slight reduction in methylphenidate use; following amphetamine withdrawal, the consumption of stimulants began to increase, and figures showed a sharp rise after marketing of extended‐release formulations in 2003. Conclusions: There has been an enormous increase in ADHD medication consumption in Castilla y León in the last few years; increase rocketed when extended‐release methylphenidate was marketed. A rapid increase in the consumption is a warning on possible overdiagnosis and inappropriate prescription. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Trends in the Prescribing of Psychotropic Medications to Preschoolers
Zito, J. M. (2000) · JAMA · doi:10.1001/jama.283.8.1025 · Cited by 863
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485
The Epidemiology of Narcolepsy
Longstreth, W. T., Koepsell, T. D., Ton, T. G., Hendrickson, A. F., & van Belle, G. (2007) · Sleep · doi:10.1093/sleep/30.1.13 · Cited by 447
National trends in the treatment of attention deficit hyperactivity disorder
Olfson, M., Gameroff, M. J., Marcus, S. C., & Jensen, P. S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1071 · Cited by 394
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Stimulant Treatment for Children: A Community Perspective
ANGOLD, A., ERKANLI, A., EGGER, H. L., & COSTELLO, E. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200008000-00009 · Cited by 353
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
ADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331
Sudden Death and Use of Stimulant Medications in Youths
Gould, M. S., Walsh, B. T., Munfakh, J. L., Kleinman, M., Duan, N., Olfson, M., Greenhill, L., & Cooper, T. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09040472 · Cited by 253
Castells, X., Ramos-Quiroga, J. A., Rigau, D., Bosch, R., Nogueira, M., Vidal, X., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11539440-000000000-00000 · Cited by 197
Continuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder
Marcus, S. C., Wan, G. J., Kemner, J. E., & Olfson, M. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.6.572 · Cited by 163
Peterson, K., McDonagh, M. S., & Fu, R. (2008) · Psychopharmacology · doi:10.1007/s00213-007-0996-4 · Cited by 135
Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†
Garnock-Jones, K. P., & Keating, G. M. (2010) · CNS Drugs · doi:10.2165/11203670-000000000-00000 · Cited by 32
Cited by
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Renoux, C., Shin, J., Dell'Aniello, S., Fergusson, E., & Suissa, S. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13000 · Cited by 132
Dalsgaard, S., Nielsen, H. S., & Simonsen, M. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0111 · Cited by 119
“Although the use of ADHD medications is generally lower in the European countries than in the United States, the same trend with increased number of prescriptions has been documented in The Netherlands, Denmark, and Spain (Hodgkins et al. 2011; Pottegard et al. 2012; Treceno et al. 2012).”
BackgroundCastells, X., Cunill, R., & Capellà, D. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1390-7 · Cited by 41
Metadata
- Authors
- Treceño, C., Martín Arias, L. H., Sáinz, M., Salado, I., García Ortega, P., Velasco, V., Jimeno, N., Escudero, A., Velasco, A., & Carvajal, A.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2012-01-17
- Volume
- 21
- Issue
- 4
- Pages
- 435-441
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W1547353064
- Cited by
- 54
- References
- 15
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.